# **Resource Summary Report**

Generated by FDI Lab - SciCrunch.org on May 9, 2025

# <u>A20</u>

RRID:CVCL\_1940 Type: Cell Line

#### **Proper Citation**

(TKG Cat# TKG 0571, RRID:CVCL\_1940)

## **Cell Line Information**

URL: https://web.expasy.org/cellosaurus/CVCL\_1940

Proper Citation: (TKG Cat# TKG 0571, RRID:CVCL\_1940)

Sex: Sex unspecified

Defining Citation: PMID:310843, PMID:22400032, PMID:28902524, PMID:31220119

**Comments:** Omics: Array-based CGH., Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981)., Part of: ENCODE project mouse cell lines.

Category: Cancer cell line

Name: A20

Synonyms: A-20

**Cross References:** BTO:BTO\_0001930, CLO:CLO\_0001564, CLO:CLO\_0050194, EFO:EFO\_0005285, ATCC:TIB-208, BCRC:60556, BCRJ:0030, BioSample:SAMN11397658, ChEMBL-Cells:CHEMBL3307765, ChEMBL-Targets:CHEMBL613850, ENCODE:ENCBS119ENC, ENCODE:ENCBS431JNZ, GEO:GSM1014167, Lonza:743, PubChem\_Cell\_line:CVCL\_1940, RCB:RCB2745, TKG:TKG 0571, TOKU-E:459, Ubigene:YC-C061, Wikidata:Q54606424

**ID:** CVCL\_1940

Vendor: TKG

Catalog Number: TKG 0571

Record Creation Time: 20250131T193540+0000

Record Last Update: 20250131T193620+0000

## **Ratings and Alerts**

No rating or validation information has been found for A20.

No alerts have been found for A20.

## Data and Source Information

Source: Cellosaurus

#### **Usage and Citation Metrics**

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Kim HY, et al. (2024) Specific targeting of cancer vaccines to antigen-presenting cells via an endogenous TLR2/6 ligand derived from cysteinyl-tRNA synthetase 1. Molecular therapy : the journal of the American Society of Gene Therapy, 32(10), 3597.

Heiser RA, et al. (2024) Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity. Molecular cancer therapeutics, 23(1), 68.

Yang Y, et al. (2024) The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor. EMBO molecular medicine, 16(4), 885.

Xue G, et al. (2024) Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy. Cancer cell.

Halász H, et al. (2024) Cooperation of Various Cytoskeletal Components Orchestrates Intercellular Spread of Mitochondria between B-Lymphoma Cells through Tunnelling Nanotubes. Cells, 13(7).

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicryrelated interferon responses in lymphoma. Leukemia, 38(10), 2210.

Middelburg J, et al. (2023) The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent. Cell reports, 42(12), 113516.

Emrich SM, et al. (2023) Orai3 and Orai1 mediate CRAC channel function and metabolic

reprogramming in B cells. eLife, 12.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Madarász T, et al. (2023) Molecular Relay Stations in Membrane Nanotubes: IRSp53 Involved in Actin-Based Force Generation. International journal of molecular sciences, 24(17).

Zeyn Y, et al. (2023) Transcriptional Targeting of Dendritic Cells Using an Optimized Human Fascin1 Gene Promoter. International journal of molecular sciences, 24(23).

Suzuki K, et al. (2023) Anti-PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases. Science immunology, 8(79), eadd4947.

Miller CL, et al. (2022) Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression. Cell chemical biology, 29(3), 451.

Ma C, et al. (2022) Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. Cancer cell, 40(9), 986.

Zhang B, et al. (2022) In Situ Tumor Vaccine Expressing Anti-CD47 Antibody Enhances Antitumor Immunity. Frontiers in oncology, 12, 897561.

Lu H, et al. (2022) Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-?B axis. Cell host & microbe, 30(8), 1139.

Rossignol J, et al. (2022) Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1. iScience, 25(6), 104353.

Mulgaonkar A, et al. (2022) ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(22), 4907.

Gozgit JM, et al. (2021) PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. Cancer cell, 39(9), 1214.

Abusarah J, et al. (2021) Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice. Cell reports. Medicine, 2(12), 100455.